FOYA winners announced
Six pharmaceutical manufacturing facilities in Europe and the US win award categories
Pfizer Health won the Facility of the Year Award for Operational Excellence at its Project Pegasus – Bio 7 manufacturing facility in Strängnäs, Sweden. This microbial drug substance production plant manufactures two legacy Pfizer hormone treatments, Genotropin and Somavert. Pfizer scientists developed a manufacturing process with virtually identical unit operations that could be used for both products.
Project Pegasus won this category for Pfizer’s ability to bring a new facility online with added capacity without increasing staff numbers or extending shift patterns. This was achieved by incorporating a high degree of flexibility into the facility design. The project team also minimised manual interactions in the process.
Control system recipes were developed that enhanced the efficiency of this biotech operation. Targeted output of the facility was previously 2 batches per week, but as a result of their focus on Operational Excellence, the facility currently has the capacity to produce 3.5 batches per week.
F. Hoffman – La Roche took the Process Innovation category award for its “MyDose” clinical supply facility in Kaiseraugst, Switzerland.
MedImmune won for Project Execution at its Frederick Manufacturing Center (FMC) expansion facility in Frederick, Maryland, US, while the Facility Integration category award went to Merck and Company for its Global Clinical Supplies Manufacturing, Packaging and Warehouse expansion project in Summit, New Jersey, US.
Novartis Vaccines and Diagnostics took the Equipment Innovation category award for its “MARS Project” facility in Marburg, Germany.
The sixth winner was Pfizer Manufacturing Deutschland, which won the Sustainability category for its SPRING & E-MAP (Strategic Plant Restructuring & Energy Master Plan) project in Freiburg, Germany.
Shire HGT received an Honourable Mention for its Project Atlas, Building 400 facility in Lexington, Massachusetts, US.
Now in its seventh year, the Facility of the Year Awards, sponsored by ISPE, Interphex and Pharmaceutical Processing magazine in the US, recognise state-of-the-art pharmaceutical manufacturing projects that incorporate new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing medicines.
The Overall Facility of the Year award will be presented during ISPE’s 2011 Annual Meeting, which takes place from 6–9 November in Grapevine, Texas, US.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Read moreHans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months